Skip to main content

Table 3 Baseline characteristics of severely diseased P. ovale cases

From: A systematic review of the clinical presentation, treatment and relapse characteristics of human Plasmodium ovale malaria

Authors, year of publication Age Sex Patient status Travel history Chemoprophylaxis
Tomar et al. [61], 2015 75 M R None, resident of India NA
Lemmerer et al. [62], 2015 29 M W Democratic Republic of Congo
Strydom et al. [36], 2014 42 M W Guinea, Mozambique None
Rojo-Marcos et al. [24], 2014 17 F
31 M
Lau et al. [8], 2013 59 M T Nigeria Mefloquine
Hachimi et al. [42], 2013 31 M Democratic Republic of Congo
Lahlou et al. [41], 2012 28 M W Democratic Republic of Congo
Roze et al. [63], 2011 24 M W Chad, Ivory Coast Doxycycline
Coton et al. [64], 2011 33 M W Djibouti
Haydoura et al. [65], 2010 46 F B NA NA
Cinquetti [66], 2010 34 M W Ivory Coast, Senegal Doxycycline
Rojo-Marcos et al. [25], 2008 43 M V Nigeria None
Rubinstein et al. [67], 2005 23 M Nigeria
Filler et al. [68], 2003 39 F T Cameroon, Botswana, Zimbabwe, South Africa Yes, drug unknown
Lee et al. [69], 1999 31 F T Ghana Mefloquine
Patel [70], 1993 42 M T Central and southern Africa NA
Facer et al. [9], 1991 51 F T Ghana None
Monlun, et al. [71], 1989 38 M T Niger Chloroquine
Bock [72], 1939 23 W Western Africa, Cameroon Chinoplasmine
20 W Western Africa, Cameroon Quinine (irregular)
Fairley [73], 1933 28 M T Nigeria, Ghana, Gambia, Sierra Leone Quinine
  1. M male, F, female, T tourist, R resident, W work, B blood transfusion, V visiting friends or relatives, NA not applicable, – not mentioned in the original publication